CMVLF Projected Dividend Yield
Cellectis SA ( OTCBB : CMVLF )Cellectis is a clinical stage biotechnological company. Co. is developing a series of product candidates for hematologic cancers. Co.'s primary immuno-oncology product candidates, which it refers to as Universal Chimeric Antigen Receptor T-cells, are allogeneic CAR T-cells engineered to be used as an off-the-shelf treatment. UCART is a therapeutic product line that it is developing with its gene-editing platform to address unmet medical needs in oncology. Co. is focusing its initial internal pipeline in the hematologic cancer space, targeting diseases such as Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma and other types of cancers. 20 YEAR PERFORMANCE RESULTS |
CMVLF Dividend History Detail CMVLF Dividend News CMVLF Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |